0000899243-19-000770.txt : 20190108 0000899243-19-000770.hdr.sgml : 20190108 20190108172001 ACCESSION NUMBER: 0000899243-19-000770 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190106 FILED AS OF DATE: 20190108 DATE AS OF CHANGE: 20190108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ebersole Nori CENTRAL INDEX KEY: 0001748293 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38667 FILM NUMBER: 19516730 MAIL ADDRESS: STREET 1: C/O UROVANT SCIENCES, INC. STREET 2: 5151 CALIFORNIA AVENUE, SUITE 250 CITY: IRVINE STATE: CA ZIP: 92617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Urovant Sciences Ltd. CENTRAL INDEX KEY: 0001740547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 5151 CALIFORNIA AVENUE STREET 2: SUITE 250 CITY: IRVINE STATE: CA ZIP: 92617 BUSINESS PHONE: 949-226-6029 MAIL ADDRESS: STREET 1: 5151 CALIFORNIA AVENUE STREET 2: SUITE 250 CITY: IRVINE STATE: CA ZIP: 92617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-06 0 0001740547 Urovant Sciences Ltd. UROV 0001748293 Ebersole Nori C/O UROVANT SCIENCES, INC. 5151 CALIFORNIA AVENUE, SUITE 250 IRVINE CA 92617 0 1 0 0 SVP;CHRO/Urovant Sciences, Inc Stock Option (Right to Buy) 6.88 2019-01-06 4 A 0 65000 0.00 A 2029-01-06 Common Shares 65000 65000 D 25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Exhibit List - Exhibit 24.1 - Power of Attorney /s/ Bryan Smith, Attorney-in-Fact 2019-01-08 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT
                             UROVANT SCIENCES LTD.
                               POWER OF ATTORNEY
                  (For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints
each of Ryan Murr of Gibson, Dunn & Crutcher LLP and Bryan Smith and Christine
Ocampo of Urovant Sciences, Inc., with full power of substitution, signing
individually, the undersigned's true and lawful attorneys-in fact and agents to:

1.  Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") Form ID,
Uniform Application for Access Codes to File on EDGAR, including amendments
thereto, and any other documents necessary or appropriate to obtain codes and
passwords enabling the undersigned to make electronic filings with the SEC of
reports required by Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or any rule or regulation thereunder;

2.  Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Exchange Act and the rules and regulations thereunder in the undersigned's
capacity as an officer, director or beneficial owner of more than 10% of a
registered class of securities of Urovant Sciences Ltd. (the "Company");

3.  Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to execute such Forms 3, 4, or 5, or Form ID
(including any amendments thereto) and timely file such forms with the SEC, and
any stock exchange, self-regulatory association or similar authority; and

4.  Take any other action of any nature whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by Gibson, Dunn
& Crutcher LLP or Urovant Sciences, Inc. or another subsidiary of the Company,
as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Date: January 8, 2019

/s/ Nori Ebersole
-----------------
Nori Ebersole